Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.
Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has launched its epilepsy research program, EPIL-A21-1, which will evaluate the effectiveness of DehydraTECH-CBD against Epidiolex, the first FDA-approved CBD treatment for seizures. The necessary test articles have been prepared and delivered to a third-party lab for dosing. Research phases will include acute and chronic seizure models, starting in May/June, with results expected by Q3 2022. The program is fully funded through existing resources, underscoring Lexaria's commitment to advancing its drug delivery technology.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the granting of its 24th patent, titled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof," enhancing its global intellectual property portfolio. This Australian patent allows the use of DehydraTECH technology for various nicotine forms, potentially increasing product value. Previous studies show DehydraTECH delivers nicotine significantly faster than conventional methods. Additionally, the company issued 36,700 stock options to staff at an exercise price of $3.39.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reported significant findings from an animal study evaluating its DehydraTECH formulation of sildenafil, showing a 74% increase in drug delivery at 4 minutes compared to a generic control. The study indicated a 70% higher maximum concentration (Cmax) and a 37% improvement in total delivery (AUC). Results showed potential for developing faster-acting sildenafil formulations. However, improvements did not achieve statistical significance, necessitating further studies.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) shared an annual letter from CEO Chris Bunka, highlighting successes and strategic directions for the company. The focus remains on advancing the DehydraTECH drug delivery technology, aimed at overcoming industry inertia and regulatory challenges. Lexaria reported a growth in shareholder base, with average shares owned by NOBO shareholders increasing by 216% in 2021. The company's institutional ownership has also surged, ranging between 9% and 16%. The aim is to leverage this momentum for potential regulatory and commercial success in 2022.
Lexaria Bioscience Corp. (NASDAQ:LEXX) recently highlighted a study demonstrating cannabinoids' potential to inhibit SARS-CoV-2 infection.
Dr. Richard van Breeman noted that oral delivery of cannabinoids is recommended over smoking or vaping for effectiveness.
Lexaria's DehydraTECH™ technology enhances cannabinoid delivery, with applications in therapeutic formulations.
The study found cannabinoid acids can block cellular entry of the virus, presenting significant implications for treatment strategies.
Lexaria holds a strong patent portfolio, with ongoing research into pharmaceutical applications.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has received early Independent Review Board approval for its DehydraTECH-CBD hypertension study, HYPER-H21-4, scheduled to begin dosing by April 2022. This study, funded through existing cash resources, aims to assess the treatment's efficacy in reducing blood pressure among 60 volunteers aged 45-70. The $28 billion hypertension market presents significant growth potential, especially in emerging economies. With a comprehensive analysis including blood pressure monitoring and brain imaging, Lexaria seeks to validate DehydraTECH-CBD as a promising anti-hypertensive therapy.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a media and digital marketing agreement with SRAX to enhance investor engagement over the next year. This follows substantial progress made by the company in 2021, with plans for an extensive 2022 including a human hypertension study and a nicotine study. Lexaria will issue 224,299 restricted shares valued at $1.2 million to SRAX for its services. The agreement aims to maximize visibility through a sustained marketing campaign, leveraging SRAX's analytical capabilities.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces the near completion of its human clinical study HYPER-H21-3, which is exploring the effects of DehydraTECH-CBD on acute pulmonary hypertension. The study involved a placebo-controlled trial with 16 volunteers receiving a 300mg dose of DehydraTECH-CBD. Blood samples are currently being analyzed, with results expected soon. This research aims to contribute to the understanding of DehydraTECH-CBD as a treatment for hypertension and will be submitted to the FDA as part of their investigational drug research program.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has released follow-up results from clinical study HYPER-H21-2, indicating that its DehydraTECH-CBD significantly reduces arterial stiffness after just one day of dosing. This finding suggests potential applications beyond hypertension, including in cardiovascular health. Notably, pulse wave velocity (PWV) was measured at 8.1 ± 0.3 m/s for DehydraTECH-CBD versus 8.3 ± 0.3 m/s for placebo, with all comparisons yielding statistically significant results (p < 0.01). Future studies, including the upcoming HYPER-H21-4, will explore these findings further.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces ambitious R&D plans for 2022, focusing on its DehydraTECH platform. Key studies include an investigation into heart disease and hypertension, as well as oral nicotine delivery alternatives. With funding of approximately USD$15 million secured, Lexaria aims to enhance drug delivery for treatments including dementia, rheumatoid disease, and diabetes. The company is debt-free and expects its cash reserves to sustain operations until at least Q2 2023. Strategic partnerships are planned post-data generation.
FAQ
What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?
What is Lexaria Bioscience Corp. known for?
In which segments does Lexaria operate?
What are the key benefits of DehydraTECH?
What is the main goal of Lexaria Bioscience Corp.?
How does DehydraTECH impact drug delivery across the blood-brain barrier?
What is the significance of Lexaria's intellectual property portfolio?
Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?
What is the focus of Lexaria's ongoing research?
How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?
What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?
